Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2011 1
2012 9
2013 47
2014 96
2015 90
2016 96
2017 95
2018 106
2019 100
2020 115
2021 111
2022 116
2023 122
2024 40

Text availability

Article attribute

Article type

Publication date

Search Results

972 results

Results by year

Filters applied: . Clear all
Page 1
Malignant peritoneal mesothelioma.
Chun CP, Song LX, Zhang HP, Guo DD, Xu GX, Li Y, Xin X, Cao J, Li F. Chun CP, et al. Am J Med Sci. 2023 Jan;365(1):99-103. doi: 10.1016/j.amjms.2022.07.008. Epub 2022 Aug 6. Am J Med Sci. 2023. PMID: 35940275 Review.
Patients should be vigilant, even though no clear risk factor is observed....
Patients should be vigilant, even though no clear risk factor is observed....
Malignant pleural mesothelioma: recent developments.
Sinn K, Mosleh B, Hoda MA. Sinn K, et al. Curr Opin Oncol. 2021 Jan;33(1):80-86. doi: 10.1097/CCO.0000000000000697. Curr Opin Oncol. 2021. PMID: 33186182 Review.
In addition to histological subtype and tumor pattern, tumor volumetry plays an increasing important role in staging, assessment of treatment response, and prediction of survival. Several new blood-based biomarkers have been recently reported including peripheral blood DNA …
In addition to histological subtype and tumor pattern, tumor volumetry plays an increasing important role in staging, assessment of treatmen …
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS. Tsao AS, et al. J Clin Oncol. 2022 Feb 20;40(6):681-692. doi: 10.1200/JCO.21.01567. Epub 2022 Jan 5. J Clin Oncol. 2022. PMID: 34985934 Free PMC article. Review.
Recent advances have led to US Food and Drug Administration approvals and changes in the standard of care with a novel biomedical device approved for use with platinum-pemetrexed, and also for immunotherapy agents to be included as a frontline treatment option in unresectable dis …
Recent advances have led to US Food and Drug Administration approvals and changes in the standard of care with a novel biomedical device app …
Immunotherapy approaches for malignant pleural mesothelioma.
Fennell DA, Dulloo S, Harber J. Fennell DA, et al. Nat Rev Clin Oncol. 2022 Sep;19(9):573-584. doi: 10.1038/s41571-022-00649-7. Epub 2022 Jul 1. Nat Rev Clin Oncol. 2022. PMID: 35778611 Review.
In mesothelioma, a rare cancer with a dismal prognosis generally caused by exposure to asbestos, treatment with single or dual ICIs results in robust improvements in overall survival over previous standard-of-care therapies, both in the first-line and relapsed disease settings. …
In mesothelioma, a rare cancer with a dismal prognosis generally caused by exposure to asbestos, treatment with single or dual ICIs results …
First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743.
Peters S, Scherpereel A, Cornelissen R, Oulkhouir Y, Greillier L, Kaplan MA, Talbot T, Monnet I, Hiret S, Baas P, Nowak AK, Fujimoto N, Tsao AS, Mansfield AS, Popat S, Zhang X, Hu N, Balli D, Spires T, Zalcman G. Peters S, et al. Ann Oncol. 2022 May;33(5):488-499. doi: 10.1016/j.annonc.2022.01.074. Epub 2022 Feb 3. Ann Oncol. 2022. PMID: 35124183 Free article. Clinical Trial.
Improved survival benefit with nivolumab plus ipilimumab versus chemotherapy was observed across subgroups, including histology. A high score of the four-gene inflammatory signature appeared to correlate with improved survival benefit with nivolumab plus ipilimumab. …
Improved survival benefit with nivolumab plus ipilimumab versus chemotherapy was observed across subgroups, including histology. A hi …
Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity.
Mangiante L, Alcala N, Sexton-Oates A, Di Genova A, Gonzalez-Perez A, Khandekar A, Bergstrom EN, Kim J, Liu X, Blazquez-Encinas R, Giacobi C, Le Stang N, Boyault S, Cuenin C, Tabone-Eglinger S, Damiola F, Voegele C, Ardin M, Michallet MC, Soudade L, Delhomme TM, Poret A, Brevet M, Copin MC, Giusiano-Courcambeck S, Damotte D, Girard C, Hofman V, Hofman P, Mouroux J, Cohen C, Lacomme S, Mazieres J, de Montpreville VT, Perrin C, Planchard G, Rousseau N, Rouquette I, Sagan C, Scherpereel A, Thivolet F, Vignaud JM, Jean D, Ilg AGS, Olaso R, Meyer V, Boland-Auge A, Deleuze JF, Altmuller J, Nuernberg P, Ibáñez-Costa A, Castaño JP, Lantuejoul S, Ghantous A, Maussion C, Courtiol P, Hernandez-Vargas H, Caux C, Girard N, Lopez-Bigas N, Alexandrov LB, Galateau-Salle F, Foll M, Fernandez-Cuesta L. Mangiante L, et al. Nat Genet. 2023 Apr;55(4):607-618. doi: 10.1038/s41588-023-01321-1. Epub 2023 Mar 16. Nat Genet. 2023. PMID: 36928603 Free PMC article.
These findings unearth the interplay between MPM functional biology and its genomic history, and provide insights into the variations observed in the clinical behavior of patients with MPM....
These findings unearth the interplay between MPM functional biology and its genomic history, and provide insights into the variations obs …
Advances in pleuroscopy.
Anevlavis S, Froudarakis ME. Anevlavis S, et al. Clin Respir J. 2018 Mar;12(3):839-847. doi: 10.1111/crj.12597. Epub 2017 Jan 11. Clin Respir J. 2018. PMID: 27997741 Review.
New Markers for Management of Mesothelioma.
Nash A, Firth Née Phan T, Creaney J. Nash A, et al. Semin Respir Crit Care Med. 2023 Aug;44(4):491-501. doi: 10.1055/s-0043-1769097. Epub 2023 May 30. Semin Respir Crit Care Med. 2023. PMID: 37253383 Review.
However, limited progress in identifying clinically useful soluble biomarkers in this cancer type has been made, with mesothelin remaining the benchmark. To date, results from studies to identify predictive biomarkers for ICI response have been disappointing. A recent retr …
However, limited progress in identifying clinically useful soluble biomarkers in this cancer type has been made, with mesothelin remaining t …
Malignant mesothelioma clinical trial combines immunotherapy drugs.
Chatwal MS, Tanvetyanon T. Chatwal MS, et al. Immunotherapy. 2018 Apr;10(5):341-344. doi: 10.2217/imt-2017-0177. Immunotherapy. 2018. PMID: 29473471
Immunotherapy-related deaths due to encephalitis, renal failure and hepatitis were observed. Further studies are warranted....
Immunotherapy-related deaths due to encephalitis, renal failure and hepatitis were observed. Further studies are warranted....
What's new in mesothelioma.
Ascoli V, Murer B, Nottegar A, Luchini C, Carella R, Calabrese F, Lunardi F, Cozzi I, Righi L. Ascoli V, et al. Pathologica. 2018 Mar;110(1):12-28. Pathologica. 2018. PMID: 30259910 Review.
Thirdly, when the diagnosis is made, despite many efforts have been made to identify possible new biomarkers for early diagnosis, prognostic stratification and also predictive tools should be defined. Nowadays, the main prognostic parameter is still represented by the hist …
Thirdly, when the diagnosis is made, despite many efforts have been made to identify possible new biomarkers for early diagnosis, prognostic …
972 results